Multiple sclerosis (MS) has long been viewed primarily as an inflammatory disease driven by peripheral immune attacks on the central nervous system. However, emerging evidence suggests that disability can progress even in the absence of clinical relapses, a phenomenon known as progression independent of relapse activity (PIRA). This has led researchers to investigate chronic active, or “smoldering,” lesions and compartmentalized inflammation within the brain and spinal cord as key drivers of ongoing tissue damage. These smoldering lesions are characterized by a rim of activated microglia and macrophages that slowly erode myelin, contributing to neurodegeneration and progressive disability. Traditional MS therapies, which largely target peripheral immune cells, may not adequately address this central nervous system compartmentalized inflammation, leaving a significant unmet need for treatments that can halt or reverse this process.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS, a patented new chemical entity that aims to protect and regenerate myelin, the protective sheath around nerve fibers that is damaged in MS. Unlike conventional immunomodulatory drugs that broadly suppress the immune system, Lucid-MS is designed to directly target myelin degradation, with the goal of preserving myelin integrity and supporting functional recovery. This approach is based on the premise that preventing myelin loss and promoting remyelination could slow or even reverse disability progression, regardless of relapse activity.
The company has also collaborated with Massachusetts General Hospital to develop a PET imaging technique that can assess myelin integrity in vivo. This tool could be invaluable in clinical trials to monitor the effect of Lucid-MS on myelin repair, providing a biomarker for treatment response. Recently, Quantum BioPharma received clearance from regulatory authorities to proceed with a Phase 2 clinical trial of Lucid-MS. This follows Phase 1 studies that reported a favorable safety profile in healthy volunteers, paving the way for efficacy testing in MS patients.
The focus on myelin protection represents a paradigm shift in MS treatment, moving beyond simply reducing inflammation to directly addressing the neurodegenerative component of the disease. By targeting smoldering lesions and the chronic inflammation within the CNS, Lucid-MS has the potential to fill a critical gap in the current therapeutic landscape. If successful, it could offer new hope for the millions of people worldwide living with MS, particularly those with progressive forms of the disease who have limited treatment options.
For more information on the recent article discussing Lucid-MS and its approach, visit https://ibn.fm/UPeUg. To stay updated on Quantum BioPharma's latest news, visit the company's newsroom at https://ibn.fm/QNTM.
